Roy M. Fleischmann, MD

Drs Roy M. Fleischmann and Joel M. Gelfand discuss addressing patient concerns to biosimilars and provide take-home messages to clinicians utilizing biosimilars.

Roy M. Fleischmann, MD, and Joel M. Gelfand, MD, MSCE, FAAD, address the importance of clinician confidence in biosimilars.

An expert rheumatologist and a dermatologist discuss challenges to bringing biosimilars to the United States.

Expert rheumatologist and dermatologist, Drs Roy M. Fleischmann and Joel M. Gelfand, discuss the impact of switching patients to biosimilars.

Drs Roy M. Fleischmann and Joel M. Gelfand discuss the roles of biosimilars and how to assess efficacy once a patient is switched to a biosimilar.

Roy M. Fleischmann, MD, and Joel M. Gelfand, MD, MSCE, FAAD, discuss the impact of biosimilars on payers, health care systems, and patients.

Expert rheumatologist and dermatologist, Drs Roy M. Fleischmann and Joel M. Gelfand discuss unmet needs in biosimilars.

Drs Roy M. Fleischmann and Joel M. Gelfand define interchangeability status and discuss its impact on the field of dermatology and rheumatology.

Drs Roy M. Fleischmann and Joel M. Gelfand explain extrapolation and how it will change the field of dermatology and rheumatology.

Roy M. Fleischmann, MD, and Joel M. Gelfand, MD, MSCE, FAAD, define the terms associated with biosimilars, including the interchangeable designation.

An expert rheumatologist and dermatologist discuss differences between biosimilars and generic drugs.

Drs Roy M. Fleischmann and Joel M. Gelfand discuss differences between biosimilars and reference products.

Roy M. Fleischmann, MD and Joel M. Gelfand, MD, MSCE, FAAD define the terms biologic and biosimilars and discuss how they are developed.